Brief: Chimeric Therapeutics Got Positive Feedback On Development Plan For CHM 2101 at Pre-IND Meeting With U.S. FDA
21/03/2023 24:48
March 21 (Reuters) - Chimeric Therapeutics Ltd CHM.AX :
* COMPLETED PRE-INVESTIGATIONAL NEW DRUG MEETING WITH US FDA
& GOT
POSITIVE FEEDBACK ON DEVELOPMENT PLAN FOR CHM 2101
Source text for Eikon: ID:nASX30blCC
Further company coverage: CHM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial